European life sciences investment firm Sofinnova Partners—which manages over €4 billion ($4.4 billion) in assets across healthcare and sustainability—has closed its second crossover vehicle, Crossover II, at €725 million ($799 million). Surpassing its initial fundraising target, it marks the largest fund in the firm’s history and is designed to bridge the late-stage financing gap between private venture capital and public markets for European biotech and medtech innovators.
📌 Fund Mandate & Portfolio Strategy:
• Closing the Scale-Up Gap: As Partner Kinam Hong noted, Europe suffers from a late-stage growth capital shortage rather than an innovation deficit—especially as regional drugmakers push policymakers for faster clinical trials and stronger medicine spending to compete with the US and China. • Concentrated Global Deployment: Crossover II plans to back ~15 late-stage companies approaching commercialization or public listings, primarily across Europe alongside selective investments in the US and international markets.
• Active Value Creation: Early investments already include rare-disease biotech Hemab Therapeutics, multiple myeloma developer CellCentric, and chronic rhinitis device maker Neurent Medical, with Sofinnova providing hands-on leadership, clinical trial, and IPO execution support.
• Proven Track Record: Its predecessor vehicle backed Amolyt Pharma (subsequently acquired by AstraZeneca) and French biotech Abivax.
💡 Market Takeaway: Late-stage crossover capital is critical for preventing promising European life sciences companies from relocating or selling prematurely due to domestic funding bottlenecks. By equipping ~15 clinical-stage innovators with institutional scale-up capital, Sofinnova is helping European biotechs build standalone global longevity.
